From: Annual public health and economic benefits of seasonal influenza vaccination: a European estimate
Influenza-related event | Numbers and costs averted additional (+) to currently averted events if VCR is increased to 75% (lower, upper limit) | |||
---|---|---|---|---|
Estimates using effectiveness values | Estimates using efficacy values | |||
Number of events averted | Costs averted | Number of events averted | Costs averted | |
Cases of influenza | +1.6 million (0.85; 2.0) | - | +1.7 million (1.1; 2.1) | - |
Influenza-related mortality | +9,843 (4,185; 14,831) | - | +14,342 (8,620; 17,939) | - |
Influenza- related GP visits | +678,482 (424,321; 849,284) | +€20 million (13; 25) | +767,787 (543,913; 935,732) | +€23 million (16; 28) |
Influenza-related hospitalization | +23,792 (11,199; 33,525) | +€ 57 million (28; 81) | +31,350 (19,545; 39,254) | +€75 million (47; 94) |
Lost days of work | +883,750 (671,094; 1,081,253) | +€112 million (85; 137) | +1,015,145 (783,557; 1,184,489) | +€128 million (99;150) |
All Influenza-related costs | - | +€190 million (125; 243) | - | +€226 million (162;272) |